Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftazidime is a third-generation cephalosporin antibiotic with broad-spectrum activity against Gram-negative and some Gram-positive bacteria. It is particularly effective against Pseudomonas aeruginosa and other resistant Gram-negative organisms. The drug acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking essential for cell wall integrity and leading to bacterial lysis. Ceftazidime is administered primarily via intravenous or intramuscular injection and is used in the treatment of serious infections such as pneumonia (including hospital-acquired), meningitis, sepsis, urinary tract infections (UTIs), skin and soft tissue infections, bone and joint infections (such as septic arthritis), intra-abdominal infections including peritonitis (especially in peritoneal dialysis patients), malignant otitis externa, and various other severe or life-threatening conditions caused by susceptible bacteria[1][5][7]. It has high stability against many beta-lactamases produced by Gram-negative bacteria but can be hydrolyzed by extended-spectrum beta-lactamases (ESBLs) or carbapenemases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftazidime.